Routine use of Beyfortus to protect infants against RSV moves closer

The US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has voted unanimously by 10 to 0 to recommend routine use of Beyfortus (nirsevimab-alip).

Sanofi (Euronext: SAN) and AstraZeneca’s (LSE: AZN) long-acting antibody has been recommended for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease for newborns and infants below eight months of age born during or entering their first RSV season.

"We have turned the corner on the threat of RSV to our youngest, most vulnerable population"The committee also voted unanimously 10 to 0 to recommend routine use of Beyfortus for children aged eight to 19 months who are at increased risk of severe RSV disease and entering their second RSV season.